Language:

2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Journal of the American College of Cardiology, 2016-09, Vol.68 (13), p.1476-1488 [Peer Reviewed Journal]

Copyright Elsevier Limited Sep 27, 2016 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.05.011 ;PMID: 27216111

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
Author: Yancy, Clyde W ; Jessup, Mariell ; Bozkurt, Biykem ; Butler, Javed ; Casey, Jr, Donald E ; Colvin, Monica M ; Drazner, Mark H ; Filippatos, Gerasimos ; Fonarow, Gregg C ; Givertz, Michael M ; Hollenberg, Steven M ; Lindenfeld, JoAnn ; Masoudi, Frederick A ; McBride, Patrick E ; Peterson, Pamela N ; Stevenson, Lynne Warner ; Westlake, Cheryl
Subjects: Cardiology ; Clinical medicine ; Colleges & universities ; Disclosure ; Gene expression ; Heart attacks ; Heart failure ; Heart Failure - drug therapy ; Heart rate ; Humans ; Mortality ; Patients ; Peer review ; Physicians ; Quality ; Sinuses ; Task forces ; Writing
Is Part Of: Journal of the American College of Cardiology, 2016-09, Vol.68 (13), p.1476-1488
Description: Given the well-proven mortality benefits of beta-blocker therapy, it is important to initiate and up titrate these agents to target doses, as tolerated, before assessing the resting heart rate for consideration of ivabradine initiation (38). [black square] This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document. Names are listed in alphabetical order within each category of review.American College of Physicians did not provide a peer reviewer for this document.AAFP indicates American Academy of Family Physicians; ACC, American College of Cardiology; AHA, American Heart Association; ASA, American Stroke Association; CHEST, American College of Chest Physicians; CIHR, Canadian Institutes of Health Research; DSMB, data safety monitoring board; FH, familial hypercholesterolemia; GWTG, Get With The Guidelines; HFSA, Heart Failure Society of America; IMAGE, Invasive Monitoring Attenuation through Gene Expression; ISHLT, International Society for Heart and Lung Transplantation; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; NQF, National Quality Forum; PCORI, Patient-Centered Outcomes Research Institute; SCAI, Society for Cardiovascular Angiography and Interventions; SUNY, State University of New York; UT, University of Texas; and VA, Veterans Affairs.
Publisher: United States: Elsevier Limited
Language: English
Identifier: ISSN: 0735-1097
EISSN: 1558-3597
DOI: 10.1016/j.jacc.2016.05.011
PMID: 27216111
Source: Geneva Foundation Free Medical Journals at publisher websites
MEDLINE
Alma/SFX Local Collection

Back to results list

Previous Result 13 Next Go to Next page


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Copyright Elsevier Limited Sep 27, 2016 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.05.011 ;PMID: 27216111

Searching Remote Databases, Please Wait